Clinical trials: Chronic Lung Diseases
COPD, Inhaled Corticosteroid
Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease (COPD)
According to the WISDOM study, withdraw of inhaled steroids has no effect on the acute exacerbation of chronic obstructive pulmonary disease (COPD), but the lung function of patients with COPD is significantly reclined.
- Trial name
- NCT04456205
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Chronic Obstructive Pulmonary Disease (COPD), COPD
Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects
The objective of the study is to evaluate the bioavailability of CHF6001 after inhaled administration, to characterize the mass balance and route of elimination of CHF6001 along with its relevant metabolites, in healthy male…
- Trial name
- NCT04756960
- Testing
- CHF6001
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD, HIV/AIDS
High-quality COPD Care for People With Immune Dysfunction Through Proactive E-consults
This study examines an intervention to promote effective, evidence-based care and de-implement inappropriate therapies for COPD in HIV-infected (HIV+) patients.
- Trial name
- ACHIEVE (NCT03856879)
- Testing
- Proactive E-consult
- Where
- 7 sites in United States
- Volunteers
- 270 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Chronic Obstructive Pulmonary Disease
COPD: A Multi-center Supervised Tele-rehabilitation Study
Chronic obstructive pulmonary disease(COPD) patients could benefit from pulmonary rehabilitation(PR) in better managing of the disease and its symptoms and in avoiding future relapses and hospitalizations.
- Trial name
- COPDMUST (NCT06085261)
- Testing
- home-based telerehabilitation group, center-based traditional rehabilitation group
- Where
- China
- Volunteers
- 360 people
- Sponsor
- China-Japan Friendship Hospital
Chronic Obstructive Pulmonary Disease
QVA Mechanistic Efficacy Study (Receptor Effects, Etc)
The purpose of this study was to assess global ventilated lung volume in moderate to severe COPD patients using MRI lung imaging after treatment with QVA149 compared to placebo.
- Trial name
- NCT02634983
- Testing
- QVA149
- Where
- 3 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease Moderate
Association of Cathelicidin and Vitamin D Levels With the Category and Course of COPD
Recruitment of patients with COPD. Assessment of clinical status, determination of vitamin D and cathelicidin levels. In the group with vitamin D deficiency, patients receive cholecalciferol (vitamin D) daily for 3 months.
- Conditions
- Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease Moderate, Chronic Obstructive Pulmonary Disease Severe
- Trial name
- COPD (NCT05431218)
- Testing
- Cholecalciferol Liquid
- Where
- Kazakhstan
- Volunteers
- 120 people
- Sponsor
- Karaganda Medical University
Chronic Obstructive Pulmonary Disease, Depression
Investigating the Impact of Mode of Administration on Item Response
The Patient-Reported Outcomes Measurement Information System (PROMIS) is an NIH Roadmap initiative to develop a computerized system measuring patient-reported outcomes in respondents with a wide range of chronic diseases and…
- Conditions
- Chronic Obstructive Pulmonary Disease, Depression, Rheumatoid Arthritis
- Trial name
- NCT00783991
- Where
- 2 sites in United States
- Volunteers
- 800 people
- Sponsor
- Stony Brook University
Long COVID, Post COVID-19 Condition
Investigating the Effectiveness of Vimida
This randomized controlled trial (RCT) with 160 patients suffering from fatigue after COVID-19 infection aims to investigate the effectiveness of the unguided digital therapeutic vimida for reducing post-COVID-19 fatigue.
- Trial name
- InvidiCO (NCT06251518)
- Testing
- vimida
- Where
- Germany
- Volunteers
- 160 people
- Sponsor
- Gaia AG
Chronic Obstructive Pulmonary Disease (COPD)
Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow.
- Trial name
- NCT07355868
- Testing
- REGEND007
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Regend Therapeutics
Chronic Obstructive Pulmonary Disease
Effect of Ketoconazole on Breathlessness
Beta-endorphins, which are naturally occurring narcotic substances, have been shown to alter the perception of breathlessness. Oral ketoconazole, an antifungal antibiotic, increases blood levels of beta-endorphins.
- Trial name
- KetoRLB (NCT01378520)
- Testing
- ketoconazole, inert powder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Chronic Obstructive Pulmonary Disease
Second Follow-up Study of COPD Patients and Healthy Controls for Evaluation of Predictive Non-coding RNA Biomarkers
Between 2012 and 2014, a cohort of 90 COPD subjects of disease severity grades GOLD I-IV as well as 60 healthy control subjects (30 smokers and 30 non-smokers) have been examined regarding different clinical and blood/ sputum…
- Trial name
- Ribo III (NCT04895124)
- Where
- Germany
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Fraunhofer-Institute of Toxicology and Experimental Medicine
COPD
Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD
This is a Randomized, Phase III, Two-period, Open-label, Chronic-dosing (7 Days), Multi-center, Crossover Study to Assess the Efficacy of PT003 in Subjects with Moderate to Severe COPD with and without a Valved Holding Chamber.
- Trial name
- NCT02454959
- Testing
- GFF MDI (PT003) with Aerochamber, GFF MDI (PT003) without Aerochamber
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ≥ 2 moderate or ≥ 1 severe exacerbations of…
- Trial name
- MIRANDA (NCT06040086)
- Testing
- Tozorakimab
- Where
- 368 sites in United States, Argentina and 27 more
- Volunteers
- 1,454 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, Urinary Incontinence
Urinary Incontinence Amongst Women With Chronic Obstructive Pulmonary Disease
The primary aim of the study is to investigate whether pelvic floor muscle training or cough-suppression therapy reduces symptoms of urinary incontinence amongst women with chronic obstructive pulmonary disease grade 1-4 (mild to…
- Trial name
- UriCO (NCT02614105)
- Testing
- Pelvic floor muscle training, Cough-suppression therapy, Control
- Where
- 2 sites in Norway
- Volunteers
- 35 people
- Sponsor
- Ostfold Hospital Trust
Chronic Obstructive Pulmonary Disease, High-flow Nasal Cannula
High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease
High-flow nasal cannula is an oxygenation technique increasingly used for patients admitted for acute respiratory failure. Literature essentially concerns "de novo" acute hypoxemic failure and the interest of high-flow during…
- Trial name
- OPTINEB (NCT03449056)
- Testing
- salbutamol
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Poitiers University Hospital
Asthma, COPD
Exhaled Breath Metabolomic Biomarkers in the Acutely Breathless Patient
An acute study carried out across three acute admissions units within Leicestershire. The study is aimed at discovery and validation of volatile organic compounds (VOCs) in exhaled breath.
- Conditions
- Asthma, COPD, Heart Failure, Community-acquired Pneumonia
- Trial name
- EMBER (NCT03672994)
- Where
- United Kingdom
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- University of Leicester
COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbations
The REVIVE Pivotal Study
The goal of this study is to test whether a new treatment called the Ryme Medical Targeted Lung Denervation (TLD) Catheter is safe and effective for people with moderate to severe chronic obstructive pulmonary disease (COPD).
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbations, COPD Patients, COPD Acute Exacerbation
- Trial name
- REVIVE (NCT07361653)
- Testing
- Ryme TLD
- Volunteers
- 300 people
- Sponsor
- Ryme Medical, Inc.
Long COVID, Multiple Chronic Conditions
The Impact of Long COVID on People Living With Pre-existing LTC
The goal of this observational study is to learn about the impact of long COVID on people who have multiple (two or more) pre-existing long-term conditions (such as diabetes and asthma).
- Trial name
- NCT06223997
- Volunteers
- 20 people
- Sponsor
- University of Leicester
High-flow Nasal Cannula, Non-invasive Positive Pressure Ventilation
The Physiological Effect of High Flow Oxygen Therapy
Although non-invasive positive pressure ventilation (NPPV) shows the good curative effect of treating the patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), some patients do not tolerate NPPV or…
- Conditions
- High-flow Nasal Cannula, Non-invasive Positive Pressure Ventilation, Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- Trial name
- NCT04212182
- Testing
- HFNC, NPPV
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Chronic Obstructive Pulmonary Disease
A COPD Quality Improvement Program（QIP）
QIP(Quality Improvement Programme) is a COPD quality improvement program in China. The initial step of this program is to set up the Quality Standards(QS) of COPD management in clinical practice, then embed Quality Standards into…
- Trial name
- QIP (NCT05638646)
- Testing
- Intervention group, control group
- Where
- China
- Volunteers
- 1,107 people
- Sponsor
- Shenzhen People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.